Roche Buys Ex-U.S. Rights to Sarepta DMD Gene Therapy Candidate SRP-9001 for Up-to-$2.85B+

Roche has acquired exclusive commercial rights outside the U.S. to Sarepta Therapeutics’ lead gene therapy pipeline candidate SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) for Duchenne muscular dystrophy (DMD), through a licensing agreement that could generate more than $2.85 billion for Sarepta.

Read the full article here

Related Articles